St George’s Respiratory Questionnaire (SGRQ)

A St George’s Respiratory Questionnaire (SGRQ) is a PRO to assess health in chronic respiratory disease (such as COPD and asthma).

• Example(s):
  • SGRQ-I.
  • SGRQ-C, includes a selection of 40 recoded items from the SGRQ.
  • ...
  • …
• Counter-Example(s):
  • a VO2 Max Test for VO2.
  • a Six-Minute Walk Test (6MWT).
• See: Chronic Respiratory Disease.

---

---

Referneces

2021

• https://eprovide.mapi-trust.org/instruments/st-george-s-respiratory-questionnaire
  • QUOTE: BASIC DESCRIPTION
    • Developed in 1991
    • Different original versions of SGRQ exist with the following recall periods (recollection of symptoms) in Part 1: 1 year recall, 4 week recall, 3 month recall (recommended version)
    • SGRQ-C: COPD-Specific Version of the SGRQ
    • SGRQ-I: Interstitial lung disease (ILD) specific, developed using the same methods as SGRQ-C
  • Authors: Jones PW
  • Objective: To assess health in chronic airflow limitation
  • Therapeutic area.
    • Respiratory Tract Diseases.
    • Immune System Diseases.
    • Hemic and Lymphatic Diseases.
    • Rare disease (Orphanet definition)
  • Therapeutic indication.
    • Asthma.
    • Pulmonary Disease, Chronic Obstructive.
    • Sarcoidosis.
    • Bronchiectasis

2005

• (Jones, 2005) ⇒ Paul W. Jones. (2005). “St . George's Respiratory Questionnaire: MCID.” COPD: Journal of Chronic Obstructive Pulmonary Disease 2, no. 1
  • ABSTRACT: The SGRQ is a disease-specific measure of health status for use in COPD. A number of methods have been used for estimating its minimum clinically important difference (MCID). These include both expert and patient preference-based estimates. Anchor-based methods have also been used. The calculated MCID from those studies was consistently around 4 units, regardless of assessment method. By contrast, the MCID calculated using distribution-based methods varied across studies and permitted no consistent estimate. All measurements of clinical significance contain sample and measurement error. They also require value judgements, if not about the calculation of the MCID itself then about the anchors used to estimate it. Under these circumstances, greater weight should be placed upon the overall body of evidence for an MCID, rather than one single method. For that reason, estimates of MCID should be used as indicative values. Methods of analysing clinical trial results should reflect this, and use appropriate statistical tests for comparison with the MCID. Treatments for COPD that produced an improvement in SGRQ of the order of 4 units in clinical trials have subsequently found wide acceptance once in clinical practice, so it seems reasonable to expect any new treatment proposed for COPD to produce an advantage over placebo that is not significantly inferior to a 4-unit difference.

2020

• (Loubert et al., 2020) ⇒ A. Loubert., A. Regnault, J. Meunier, F. S. Gutzwiller, and S. A. Regnier. (2020). “Is the St. George’s Respiratory Questionnaire An Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD?" In: International Journal of Chronic Obstructive Pulmonary Disease, Volume:15. https://doi.org/10.2147/COPD.S261919
  • QUOTE: ... The SGRQ is a PRO instrument developed to assess the health status of patients with COPD and asthma.4 It includes 50 items assessing three domains: Symptoms (severity and frequency of respiratory symptoms), Activity (effect of disease on common daily physical activitiees) and Impact (psycho-social effects of the disease). A total composite score can be calculated using all SGRQ items as well as three domain scores. A COPD-specific version, the SGRQ-C, includes a selection of 40 recoded items from the SGRQ.12

1992

• (Jones et al., 1992) ⇒ Paul W. Jones, Frances H. Quirk, Chloe M. Baveystock, and Peter Littlejohns. (1992). “A Self-complete Measure of Health Status for Chronic Airflow Limitation.” Am Rev Respir Dis, 145(6).

---